Sign In
Buy IONS
$72.97
-2.41 (-3.20%)
At Close: Jun 02, 2026
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
12:32pm, Friday, 29'th May 2026
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
03:32pm, Thursday, 28'th May 2026
Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. IONS is transitioning from niche indications to multi-billion-dollar markets, leveraging
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
08:07pm, Monday, 25'th May 2026
Ionis Pharmaceuticals NASDAQ: IONS highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets' Global Healthcare Conference
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
10:10am, Tuesday, 19'th May 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
06:05am, Monday, 18'th May 2026
Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
12:31pm, Friday, 15'th May 2026
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating dirane
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
05:30pm, Tuesday, 12'th May 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GSK Targets China's Hepatitis B Market Through New Deal
12:03pm, Monday, 11'th May 2026
GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while launching its final buyback tranche.
Tweedy Browne's Strategic Moves: Ionis Pharmaceuticals Inc. Sees Significant Reduction
06:08pm, Wednesday, 06'th May 2026
Analyzing the Impact of Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing Tweedy Browne (Trades, Portfolio) recently submitted the 13F filing for the first
Ionis to host 2026 virtual Annual Meeting of Stockholders
07:05am, Monday, 04'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corpora
Ionis to present at upcoming investor conferences
07:05am, Friday, 01'st May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
04:01pm, Wednesday, 29'th Apr 2026
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
